Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

This content is available also in other languages


This content is available also in other languages

The Blog

Selected category: Cancer

Back to overview

Considering mass spec for therapeutic drug monitoring? Here are 4 pitfalls to avoid

By Dr Manuel Bauer 

As we saw in part 1 of this blog series, liquid chromatography-tandem mass spectrometry (LC-MS/MS) is potentially the new gold standard for therapeutic monitoring of immunosuppressant drugs (ISD). However, for this technology to become widely adopted, the methodology needs to be standardized globally, including addressing bottlenecks both at the pre-analytical stage of sample preparation, and within the process itself. Here we take a look at the top four pitfalls to avoid when implementing LC-MS/MS for ISD monitoring.

Read more
empty cart | close cart
Your cart

Your cart is empty.

Get a quote close form